Syndax Pharmaceuticals, Inc. (SNDX) Financials
SNDX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 612.9 million | 58.7 million |
2023-09-30 | 399.2 million | 40.0 million |
2023-06-30 | 431.3 million | 31.3 million |
2023-03-31 | 459.8 million | 24.3 million |
SNDX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -41.3 million | 8.3 million |
2023-09-30 | -44.7 million | 8.3 million |
2023-06-30 | -35.4 million | 8.1 million |
2023-03-31 | -39.2 million | 6.2 million |
SNDX Net Income
No data available :(
SNDX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 577.6 million | - | 1.6 million |
2023-09-30 | 373.8 million | - | 1.9 million |
2023-06-30 | 406.0 million | - | 2.1 million |
2023-03-31 | 449.0 million | - | 1.1 million |
SNDX Shares Outstanding
SNDX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 55.1 million | 44.1 million | 21.4 million |
2023-09-30 | - | 39.1 million | 17.3 million | - |
2023-06-30 | - | 34.8 million | 14.9 million | - |
2023-03-31 | - | 34.1 million | 12.0 million | - |
SNDX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 536000 | 268000 |
2023-09-30 | - | 3000 |
2023-06-30 | - | 152000 |
2023-03-31 | - | 113000 |
SNDX
Price: $22.60
52 week price:
Earnings Per Share: -2.98 USD
P/E Ratio: -8.53
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 44479
Ebitda: -15.3 millionMarket Capitalization: 1.9 billion